At a Glance
Bottom Line: The direction is clear, but the timeline is not. Operators who model the post-280E environment now will be positioned to act when the final rule takes effect.
On December 18, 2025, President Trump signed an executive order directing the Attorney General to expedite completion of the federal rulemaking process to move cannabis from Schedule I to Schedule III. The order follows a 2023 recommendation from the Department of Health and Human Services (HHS), which found over 30,000 healthcare practitioners recommending medical cannabis to more than 6 million patients for at least 15 medical conditions. The order also addresses hemp-derived cannabinoid products, directing the administration to work with Congress on access pathways ahead of new federal restrictions on intoxicating hemp-derived products.
Days earlier, on December 15, 2025, the Supreme Court denied certiorari in Canna Provisions v. Bondi. For near-term, nationwide change, the administrative rulemaking process is the path to watch.
The executive order is significant. It is not immediate relief.
Section 280E applies to businesses trafficking in controlled substances “within the meaning of Schedule I or II.” Until the Drug Enforcement Administration (DEA) completes formal rulemaking and the final rule becomes effective, cannabis remains Schedule I and 280E continues to apply.
Federal guidance has not yet clarified whether relief will be retroactive to the start of the tax year in which the rule takes effect or apply only from the effective date forward. Operators should model both scenarios.
Under 280E, cannabis operators face effective federal tax rates that can exceed 70%. Ordinary business deductions are disallowed; only cost of goods sold reduces taxable income. When rescheduling takes effect, ordinary deductions become available, potentially dropping effective rates to normal business taxation levels, including the 21% corporate rate for C-corps.
For operators in states that conform to 280E, the savings compound. State treatment varies widely: some major states including California and New York have decoupled, meaning operators already receive state-level deductions. Many other states key off federal taxable income, so rescheduling would provide both federal and state relief in those jurisdictions. The state-by-state analysis is fact-specific and depends on each operator’s footprint.
This shift changes after-tax cash flows, working capital requirements, and estimated tax obligations. If the effective date lands mid-year, the timing of when expenses are incurred may matter. As the income profile changes, tax attribute planning warrants review.
Many cannabis operators perform qualifying research activities that generate no federal tax benefit under 280E. Post-rescheduling, two separate benefits become available.
First, the Section 41 R&D tax credit rewards qualified research expenditures with a dollar-for-dollar reduction in tax liability. The credit requires technological uncertainty, a process of experimentation, and a permitted purpose. Qualifying activities extend well beyond cultivation and extraction to include formulation, manufacturing processes, and proprietary systems development.
Second, under OBBBA’s Section 174A, domestic research and experimental expenditures can be immediately expensed rather than capitalized over five years. Foreign R&E remains subject to 15-year amortization, but for U.S. operators, qualifying R&D activities are typically domestic, making this provision particularly valuable.
R&D credit claims require coordinating the credit with expense treatment, including the Section 280C election mechanics. State-level credits that were irrelevant under 280E economics may also warrant review. For operators with meaningful research profiles, the combined benefit creates substantial tax savings worth quantifying before the rule takes effect.
Cannabis operators are often structured around regulatory and banking constraints rather than tax efficiency. Post-280E, new opportunities emerge.
Filing elections, including federal consolidated return status, may warrant review as the post-280E math changes. Intercompany arrangements and transfer pricing, often structured to account for 280E limitations, should be revisited.
The “taint” concern also diminishes. Under 280E, the Tax Court has held that activities supporting cannabis operations can themselves be subject to 280E’s disallowance. In Alternative Health Care Advocates v. Commissioner (2018), a management company providing services to a dispensary was itself found to be trafficking in controlled substances, subjecting both entities to 280E. Post-rescheduling, this risk largely disappears, and support functions can be structured without concern for contaminating otherwise-deductible expenses.
Rescheduling should increase after-tax earnings, which flows directly to enterprise valuations. Buyers and sellers should consider how post-280E economics affect deal pricing and structure.
Purchase price allocation strategy also shifts. Allocations to amortizable intangibles produce real deductions in a post-280E environment, changing how buyers approach the negotiation.
Earnout structures also warrant attention. Where earnouts are tied to EBITDA or cash flow metrics, definitions should explicitly address the tax transition period to avoid disputes over whether the earnout baseline was intended to reflect 280E economics.
Tax representations and warranties in transaction documents will need updating as well. Reps drafted for a 280E world may not adequately address the transition period or post-rescheduling compliance.
For operators in active disputes, rescheduling changes the landscape.
It’s not just that 280E created high effective tax rates. It’s that every examination became more productive for the IRS. A 2020 report from the Treasury Inspector General for Tax Administration (TIGTA) found cannabis examinations averaged $2,752 in assessments per examination hour, compared to $1,065 for mainstream businesses. This disparity exists because 280E concentrates all tax disputes into a single area: every dollar excluded from COGS becomes taxable income with no offset available.
When 280E no longer applies, that dynamic may diminish. Audit focus shifts from COGS classification and 280E disallowances to more typical expense substantiation issues.
The impact extends to collections. In Mission Organic Center, Inc. v. Commissioner, decided December 16, 2025, the Tax Court upheld the IRS’s rejection of an offer in compromise (OIC) where 280E’s disallowance of deductions distorted the taxpayer’s reasonable collection potential. Post-rescheduling, OIC calculations should more accurately reflect actual financial condition.
For operators with open audit years, strategic questions arise: whether to accelerate resolution of current disputes or wait for timing clarity on the effective date.
Post-280E, international tax modeling becomes cleaner. Section 280E’s interaction with foreign subsidiaries and deemed-income computations has been messy, and published guidance limited. Removing that uncertainty simplifies deemed income calculations for controlled foreign corporations (CFCs) under Subpart F and the net CFC tested income (NCTI) rules, as well as foreign tax credit availability and limitations.
The outcomes still depend on entity structure and expense allocation, but the analysis is no longer distorted by 280E’s blanket disallowance. For operators modeling 2026 and beyond, OBBBA’s NCTI transition timing should be incorporated into the broader forecast.
The executive order signals clear direction. The operators who model the post-280E environment now will be positioned to act when the final rule takes effect.
Sapowith Tax Advisory helps cannabis operators navigate 280E planning, entity structuring, and tax controversy. We combine technical depth with practical experience across cultivation, manufacturing, distribution, retail, and vertically integrated operations.
Our approach recognizes that tax positions must align with operational realities and withstand examination. From single-state dispensaries to multi-state enterprises, we provide planning calibrated to each client’s circumstances and risk tolerance.
Contact us to discuss how the rescheduling transition affects your specific situation. In cannabis taxation, positioning ahead of regulatory change often determines who captures the upside.
This article is for general information only; it is not tax, legal, or accounting advice. Reading it does not create a client relationship with Sapowith Tax Advisory. Consult your own qualified advisers before acting on any information contained here. Sapowith Tax Advisory disclaims all liability for actions taken, or not taken, based on this content.